PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.76%
Positive EBIT growth while AGEN is negative. John Neff might see a substantial edge in operational management.
10.76%
Positive operating income growth while AGEN is negative. John Neff might view this as a competitive edge in operations.
11.35%
Positive net income growth while AGEN is negative. John Neff might see a big relative performance advantage.
31.03%
Positive EPS growth while AGEN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
31.72%
Positive diluted EPS growth while AGEN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
29.31%
Slight or no buybacks while AGEN is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
29.44%
Slight or no buyback while AGEN is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
2.31%
Positive OCF growth while AGEN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
3.06%
Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-254578.19%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
64.50%
Positive OCF/share growth while AGEN is negative. John Neff might see a comparative advantage in operational cash viability.
73.57%
Positive 3Y OCF/share CAGR while AGEN is negative. John Neff might see a big short-term edge in operational efficiency.
-9976.84%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-124.34%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
76.73%
Positive short-term CAGR while AGEN is negative. John Neff would see a clear advantage in near-term profit trajectory.
1493.31%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-38.28%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-74.77%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.33%
Positive asset growth while AGEN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
127.26%
Positive BV/share change while AGEN is negative. John Neff sees a clear edge over a competitor losing equity.
-9.95%
We’re deleveraging while AGEN stands at 6.47%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-7.53%
Our R&D shrinks while AGEN invests at 12.74%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-21.01%
We cut SG&A while AGEN invests at 5.55%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.